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Background: Due to the world-wide increase in treatments involving implant placement, the incidence of peri-implant
disease is increasing. Late implant failure is the result of the inability to maintain osseointegration, whose most important
cause is peri-implantitis. The aim of this study was to analyze the clinical, microbiological, and immunological aspects in
the peri-implant sulcus fluid (PISF) of patients with healthy dental implants and patients with peri-implantitis.
Methods: PISF samples were obtained from 24 peri-implantitis sites and 54 healthy peri-implant sites in this prospective
cross-sectional study. The clinical parameters recorded were: modified gingival index (mGI), modified plaque index (mPI)
and probing pocket depth (PPD). The periodontopathogenic bacteria Tannerella forsythia, Treponema denticola and
Porphyromonas gingivalis were evaluated, together with the total bacterial load (TBL). PISF samples were analyzed for
the quantification of Interleukin (IL)-8, IL-1β, IL-6, IL-10 and Tumor Necrosis Factor (TNF)-α using flow cytometry (FACS).
Results: The mGI and PPD scores in the peri-implantitis group were significantly higher than the healthy group
(p < 0.001). A total of 61.5% of the patients with peri-implantitis had both arches rehabilitated, compared with
22.7% of patients with healthy peri-implant tissues; there was no implant with peri-implantitis in cases that received
mandibular treatment exclusively (p < 0.05). Concentrations of Porphyromonas gingivalis (p < 0.01), association with
bacteria Porphyromonas gingivalis and Treponema denticola (p < 0.05), as well as the TBL (p < 0.05) are significantly
higher in the peri-implantitis group. IL-1β (p < 0.01), IL-6 (p < 0.01), IL-10 (p < 0.05) and TNF-α (p < 0.01) are significantly
higher at the sites with peri-implantitis compared to healthy peri-implant tissue, while IL-8 did not increase significantly.
Conclusion: The results of the present study involving a limited patient sample suggest that the peri-implant
microbiota and which dental arch was rehabilitated involved could contribute to bone loss in peri-implantitis. A
significant relationship is observed between the concentration of cytokines (interleukins 1β, 6 and 10 and TNF-α)
and the inflammatory response in peri-implantitis tissue.
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The restoration of missing teeth by means of dental im-
plants has now become a routine treatment in common
use [1]. Various longitudinal studies have shown the high
survival rates of implants in functional use, which range
between 90% and 95% over a follow-up period of up to
20 years [2-4]. Peri-implant disease infection etiology has
been described in detail in the literature for both mucositis
[5-8] and peri-implantitis [9-12]. Late implant failure is
the result of the inability to maintain osseointegration,
whose most important cause is peri-implantitis [1].
Using the checkerboard DNA-DNA hybridization
method, Socransky et al. [13] identified a consortium of
the bacterial species Tannerella forsythia (T. forsythia),
Treponema denticola (T. denticola) and Porphyromonas
gingivalis (P. gingivalis) as having the highest association
with periodontal disease severity. The authors named
this microbial consortium “red complex”. Evaluation of
the literature has shown the microbiota associated to
peri-implantitis to be more complex than that found
under healthy peri-implant conditions – the main flora
consisting of anaerobic gram-negative bacteria [14]. A
high degree of association between this red complex and
the appearance of peri-implantitis has been observed
[9-12,14]. However, in healthy peri-implant sulci, oral
streptococci constitute the predominant bacterial flora [15].
Although different cytokines have been evaluated
[16-18], the cytokine concentrations that differentiate
between healthy and stable sites and the onset of a
pathological periodontal and peri-implant process are
not known [19]. In the periodontium, individual differ-
ences in inflammatory and immunological responses to
bacterial infection may influence the host’s susceptibility
to disease [20]. The cascade of inflammatory mediators
of the host in response to bacterial infection, which can
result in destruction of connective tissue and bone, is
determined by genetic factors [21].
The aim of this study was to study the clinical charac-
teristics of peri-implantitis as established by the modified
plaque index, modified gingival index and probe depth,
examines the microbial and host response Interleukin
(IL)-8, IL-1β, IL-6, IL-10 and Tumor Necrosis Factor
(TNF)-α characteristics in dental implants with peri-




This is a prospective cross-sectional study of clinical,
microbiological and immunological markers of 24 peri-
implantitis and 54 healthy peri-implant sites. Sixty-six
patients were treated at the Department of Oral Surgery
and Implantology at Valencia University Medical and
Dental School (Valencia, Spain). All patients presentedat least one completely edentulous dental arch, which
were rehabilitated with dental implants (Figure 1). All
patients were seen by a single examiner (JAA). The
study was conducted in accordance with the Helsinki
Declaration and the protocol was approved by the
institutional review board of the University of Valencia;
patients gave their informed consent to participate in
the study in writing.
We excluded those patients who had received any kind
of local or systemic decontamination treatment of the
oral cavity in the previous three months (such as antibi-
otics or rinses), or periodontal treatment in the previous
six months. Patients with uncontrolled periodontal dis-
ease (assessed by a specialist in periodontics) were also
excluded, in the same way as individuals presenting
implants with exposure of the rough surface, patients
with systemic diseases (e.g., HIV infection or leukemia)
or who were in receipt of drugs capable of altering
gingival health in some way, or pregnant women and
nursing mothers (Figure 1).
The study population consisted of 35 individuals
(22 patients with healthy implants and 13 with peri-
implantitis). Seventy-eight dental implants were evalu-
ated during the study (24 with peri-implantitis and 54
healthy peri-implant sites). Phibo® treatment surface
Avantblast (TSA) implants (Phibo Dental Solutions,
Sentmenat, Barcelona, Spain) had been implanted in the
patient sample, and all implants had been in functional
use for at least 24 months. The data collected was ana-
lyzed, relating them to age, sex, smoking, oral hygiene,
which arch had been rehabilitated and the type of pros-
thesis (Table 1).
Implant inclusion criteria
The patients were divided into two groups according to
whether or not they presented peri-implantitis. Peri-
implantitis was defined according to Schwarz et al. [22]:
implant with a probing depth ≥4 mm and signs of acute
peri-implantitis (loss of supporting bone as estimated
on radiographs, bleeding on probing or suppuration)
and no implant mobility. The inclusion criteria in the
group of patients with healthy dental implants were:
probing pocket depth (PPD) < 4 mm [17,23,24], absence
of clinical signs of inflammation of the peri-implant
mucosa, and without radiographic bone loss. If one of
the implants was healthy but another showed signs of
peri-implantitis, the patient was classified as having the
disease.
The implant with the deepest peri-implant pocket was
selected for collection of the microbiological samples
and for determining interleukins, selecting one implant
from each rehabilitated quadrant. When there were two
or more implants with the same probe depth, the most
anteriorly positioned implant was selected.
Figure 1 Diagram showing patients included and excluded from the study.
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We examined all the implants in each patient, recording
the implant data per rehabilitated quadrant in each sub-
ject (registering two or four implants according to
whether the upper maxilla, the mandible, or both were
rehabilitated). The modified gingival index (mGI) and
the modified plaque index (mPI) were determined for each
implant according to methods described by Mombelli
et al. [25]. The peri-implant probing pocket depth (PPD)
was measured with a probe calibrated to 0.25 Nw (Click
Probe, Kerr, USA). Specifically, PPD was measured at
the mesiobuccal, mediobuccal, distobuccal, mesiolingual,mediolingual and distolingual points of each implant, and
the mean PPD was calculated for each implant [26].
Radiographic evaluation
Marginal bone loss was measured from the intraoral X-
ray studies, using the XMind® intraoral system (Groupe
Satelec-Pierre Rolland, Bordeaux, France) and the RVG®
intraoral digital receptor (Kodak Dental System, Atlanta,
GA, USA). The XCP® X-ray positioning device (Dentsply,
Des Plaines, IL, USA) was used to reproduce the angle of
the X-rays in later reviews. In order to position the XCP®
correctly, the guide bar was placed parallel to the direction
Table 1 Demographic and clinical description of the study population
Healthy Peri-implantitis Differences
per group
Age (mean ± s.d.) 63.6 ± 10.4 52 ± 7.7 **
Gender (% females) Number of patients Number of implants 59.1 22 54 53.8 13 24 n.s.
Smoking habit Non-smokers (%) 100.0 38.5 **
Smokers (%) 0.0 61.5
Oral hygiene Never (%) 0 7.7 n.s.
1-2 times/day (%) 63.6 46.2
3 times/day (%) 36.4 46.2
Rehabilitated arch Upper (%) 31.8 38.5 *
Lower (%) 45.5 0
Both (%) 22.7 61.5
Prosthesis1 Fixed (%) 31.8 38.5 n.s.
OD Locator® (%) 45.5 7.7 *
OD Bar (%) 9.1 38.5 *
Fixed and OD Locator (%) 4.5 0
OD Locator and OD Bar (%) 4.5 7.7
OD Bar and hybrid (%) 4.5 0.0
Hybrid (%) 0.0 7.7
Chi-squared test for evaluating differences in gender and type of prosthesis between groups.
Mann-Whitney U-test for evaluating differences in smoking, brushing and arch between groups.
Student t-test for evaluating age differences between groups.
Note: Only differences in the proportion of the three most frequent types of prostheses are evaluated.
n.s. = nonsignificant.
OD = overdenture; Locator® (Zest Anchors, Escondido, CA, USA).
s.d. = standard deviation.
*p < 0.05; **p < 0.01.
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According to the VII European Workshop in Periodon-
tology, to establish the baseline, a radiograph should
be obtained to determine alveolar bone levels after
physiological remodeling, and peri-implant probing
assessments should not be performed before this has
taken place as it is assumed that bone loss occurring
after initial remodeling is mainly due to bacterial
infection [27].
PISF sampling
Peri-implant sulcus fluid (PISF) was collected from each
implant after the presence or absence of plaque (mPI)
had been assessed and before registering any other
clinical parameters [26]. After calibrating the Periotron®
8000 (Proflow Incorporated. New York, USA), the PISF
sample was collected with sterile paper strips (Periopa-
per Strip® Proflow Incorporated. New York, USA).
The technique used was as follows: a) drying the
mouth with aspiration; b) isolation of the zone with cot-
ton rolls; c) gentle drying of the zone; d) sulcus fluid
sampling by placing the sterile paper strips in the sulcus
between the implant and gums, keeping this position for
30 seconds; e) placement between the sensors of thePeriotron® 8000, to record the amount of PISF obtained
in Periotron units previously calibrated following the
manufacturer’s indications.
PISF was absorbed by each strip. Each sample was
diluted in an Eppendorf tube with 200 μL of 50 mM
phosphate buffer, pH 7.2, together with a pool of prote-
ase inhibitors (Roche Diagnostics GmbH, Mannheim,
Germany) and 0.1 mM phenyl sulfonyl fluorate, and in-
cubated for two hours. The samples were centrifuged at
1000 g for five minutes, and the supernatant was stored
at -80°C until used.
Cytokine assay
IL-1β, 6, 8, 10 and TNF-α cytokines were evaluated in
the supernatants stored at -80°C. The evaluation was
performed by using the Human Inflammation Cytomet-
ric Bead Array (CBA) system (Becton Dickinson, BD
Biosciences, San Diego, CA, USA) and FACS analysis
(Becton Dickinson, BD Biosciences, San Diego, CA, USA).
The samples and positive controls (standard curve) were
processed according to the manufacturer’s instructions,
and the values for cytokines were calculated and reported
as pg/ml. Data were acquired with a FACS calibur flow
cytometer (Becton Dickinson, Franklin Lakes, NJ, USA).
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Supragingival plaque was removed from the implant
with the deepest peri-implant pocket in each quadrant
using a curette or cotton roll, without penetrating the
gingival sulcus. Cotton rolls were used for relative isola-
tion. The sampling site was dried with an air pistol. Sterile
paper tips (Johnson & Johnson, Medical Inc., Arlington,
TX, USA) were inserted in the peri-implant sulcus for
10 seconds. The paper tips were then thoroughly impreg-
nated in a solution of guanidine thiocyanate 4 M and
2-mercaptoethanol contained in a tube. For micro-
biological analysis, the samples were sent to IAI, Inc.,
where analyses were made of T. forsythia, P. gingivalis,
T. denticola and the total bacterial load (TBL) using the
IAI-PadoTest 4.5® (IAI Inc., IAI Institute, Zuchwill,
Switzerland), a method used by other researchers [28-30].
To this effect, the samples were mounted in nylon mem-
branes and hybridized with specific P32 probes directed
against the sRNA ribosomal subunit of the three above
mentioned periodontal bacterial species.
Statistical analysis
The SPSS version 15.0 statistical package for Microsoft
Windows (SPSS Inc., Chicago, IL, USA) was used for
statistical analysis. Tables 1 and 2 show the statistical
tests used for each measure. Statistical significance was
considered for p < 0.05. The statistical power reached by
the Mann-Whitney U-test (used in comparing the 24
implants with peri-implantitis versus the 54 withoutTable 2 Clinical characteristics of the implants with
healthy peri-implant gingiva and with peri-implantitis
Healthy Peri-implantitis Differences
per group
Mean PPD in mm 2.72 ± 0.59 5.15 ± 0.68 *
mPI 0.96 ± 1.03 1.25 ± 1.15 n.s
0 (%) 46.3 37.7
1 (%) 18.5 16.7
2 (%) 27.8 29.2
3 (%) 7.4 16.7
mGI 0.63 ± 0.92 2.71 ± 0.46 *
0 (%) 63.0 0
1 (%) 14.8 0
2 (%) 18.5 29.2
3 (%) 3.7 70.8
PISF 91.7 ± 50.3 83.9 ± 43.1 n.s.
Mean ± s.d. or %, as indicated.
*p < 0.001.
Mann-Whitney U-test for evaluating differences in PPD, mPI and mGI
between groups.
Student t-test for evaluating differences in PISF between groups.
n.s. = nonsignificant.
PPD = probe pocket depth; mPI = modified plaque index; mGI =modified
gingival index; PISF = peri-implant sulcus fluid.peri-implantitis) in the bacterial load analysis in the sample
of 78 implants was 0.88. A detected effect size of 0.8
was assumed, with a 95% confidence level (α = 0.05).
Results
Table 1 reports mean patient age (p<0.01), gender, smoking
habits (p<0.01), oral hygiene, which arch was rehabilitated
(p < 0.05) and prosthetic type (p<0.05) for the two study
groups. When prosthetic type was registered, Locator®
supporting an overdenture was the most frequent in the
patient group with healthy peri-implant sites, while over-
dentures on bars were the most frequent in implants with
peri-implantitis. A total of 61.5% of the patients with peri-
implantitis had both arches rehabilitated, compared with
22.7% of patients with healthy peri-implant tissues; there
was no implant with peri-implantitis in cases that received
mandibular treatment exclusively.
The mean values of clinical parameters for all implants
(with or without peri-implantitis) are presented in
Table 2. There were no statistically significant differences
in the percentage of sites at which plaque was found
between the groups. mGI scores were significantly
higher around implants with peri-implantitis than
around healthy implants (p < 0.001). The recorded mean
PPDs in the peri-implantitis group and the healthy group
were 5.15 ± 0.68 and 2.72 ± 0.59, respectively, this being a
statistically significant difference (p < 0.001) (Figure 2). On
examining the PISF volumes, no significant differences
were observed between the two groups.
The analysis of putative periodontal pathogens of the
red complex (T. forsythia, P. gingivalis, T. denticola) and
total bacterial load (TBL) are summarized in Table 3.
Subgingival microbiota was composed of a greater number
of periodontal pathogens in patients with peri-implantitis,
showing significant difference in counts of P. gingivalis
(p < 0.01), in P. gingivalis and T. denticola association
(p < 0.05), as well as TBL (p < 0.05).
The peri-implantitis group showed a significantly
greater level of IL-6 than the healthy group (0.96 ± 0.64
and 0.53 ± 0.63 respectively, p < 0.01); IL-1β (58.5 ± 84.8
and 21.2 ± 24.2 respectively, p < 0.01); IL-10 (0.91 ± 0.90
and 0.45 ± 0.87 respectively, p < 0.05); TNF- α (1.08 ±
1.49 and 0.25 ± 0.56 respectively, p < 0.01) (Figures 3
and 4). Although IL-8 increased in the peri-implantitis
group, there was no statistically significant difference
in comparison with the healthy implant group. The
IL-1β/ IL-10 ratio was found to be 9.9 ± 11.9 for the
healthy group and 37.2 ± 44.4 for the peri-implantitis
group (p = 0.006).
Discussion
Due to the world-wide increase in treatments involving
implant placement, the incidence of peri-implant disease
is increasing. Initial screening of peri-implant tissues will
Figure 2 The mGI and PPD values for the peri-implantitis group were significantly higher than in the healthy group.
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depth and the degree of bleeding on probing [31]. When
increased bacterial plaque and bleeding in response to
probing affects over 30% of the dental implants, this
situation is related to a high risk of mucositis and peri-
implantitis [32]. A study [33] involving 34 patients with
77 dental implants (comprising 23 mucositis and 54
healthy periimplant sites) concluded that bacterial
plaque induces an inflammatory response that can lead
to the development of peri-implant mucositis. A recent
systematic review [34] highlights the lack of uniform
treatment and the need to establish additional research
to fully provide effective treatments for this common
condition, which is the first step to prevention peri-
implantitis. These data are consistent with those pub-
lished by Shibli et al. [11], which found patients with
peri-implantitis to have increments in all the evaluated
clinical parameters, except the percentage of locations
with bacterial plaque. mGI score and PPD are parameters
that must be evaluated for the diagnosis of peri-implant
disease [27,28,32]. Accordingly, the present study foundTable 3 Detection frequencies of target bacteria in subgingiv
T. forsythia (Tf) P. gingivalis (Pg) T. denticol
Healthy 12 (22.2%) 6 (11.1%) 9 (16.7%)
Peri-implantitis 8 (33.3%) 9 (37.5%) 8 (33.3%)
Differences per group n.s. ** n.s.
Chi-squared test for evaluating differences in bacterial presence between groups.
n.s. = nonsignificant.
*p < 0.05; **p < 0.01.
Tf: Tannerella forsythia (T. forsythia); Pg: Porphyromonas gingivalis (P. gingivalis); Td
Red Complex = Tf + Pg + Td.
TBL = Total Bacterial Load.that both mGI and PPD were significantly higher in the
implants with peri-implantitis (p < 0.001).
Most studies regarding risk factors for peri-implant
disease have concluded that smoking is clearly involved
[35-40]. This is also supported by the present study, in
which a significant relationship was found between
smoking and the presence of peri-implantitis. However,
such data should be viewed with caution, since the
group with healthy implants consisted of non-smokers;
consequently, smoking could not influence the clinical,
microbiological and immunological parameters studied.
Patients with peri-implantitis were significantly younger
on average than patients with healthy peri-implant tissues,
a finding that differs from other studies in which older
patients showed higher rates of peri-implantitis [41]. In
this population, when prosthetic type was studied, it
was found that overdentures supported by Locator®
were more frequent among patients with healthy peri-
implant tissues, while overdentures on bars were more
frequent on implants with peri-implantitis. In a study
by Marrone et al. [41] more cases of peri-implantitisal peri-implant sites for each group
a (Td) TBL Tf + Pg Tf + Td Pg + Td Red complex
52 (96.3%) 6 (11.1%) 6 (11.1%) 6 (11.1%) 6 (11.1%)
24 (100%) 6 (25%) 6 (25%) 8 (33%) 6 (25%)
n.s. n.s. n.s. * n.s.




Figure 3 Differences in IL-6 (p < 0.01), IL-10 (p < 0.05) and TNF-α (p < 0.01) in patients with peri-implantitis and in patients with healthy
peri-implant tissues (pg/ml).
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patients rehabilitated with fixed prostheses, which agrees
with the present results. A total of 61.5% of the patients
with peri-implantitis had both arches rehabilitated,
compared with only 22.7% of patients with healthy peri-
implant tissues, and there were no cases of implants
with peri-implantitis who had undergone rehabilitation
of the mandible exclusively.
P. gingivalis was detected in the half of gingivitis patients
and in more than 80% of the periodontitis patients-
derived samples [42]. High counts of T. forsythia, P. gingi-
valis and T. denticola have been observed in implants with
peri-implantitis [9-12]. For the first time, a study demon-
strated that the red complex periodontal bacterium Pg
produces a concentration of Hydrogen sulfide capable of
up-regulating IL-8 expression induced in gingival and oralFigure 4 Differences in IL-1β (p < 0.01) and IL-8 in patients between pepithelial cells, revealing a possible mechanism that may
promote the inflammation in periodontal disease [43]. In
the present study there was a significant relation between
peri-implantitis and P. gingivalis, association with P. gingi-
valis and T. denticola, and total bacterial load. Other
studies [14,44-47] found these bacteria in patients with
healthy peri-implant tissue, which was similar to the
present sample of healthy peri-implant patients, in
which red complex was found at 11.1% of healthy peri-
implant sites, while red complex was found at 25% of
implants with peri-implantitis. In a study by Nowzari
et al. [23] it was found that 16.7% of healthy peri-
implant tissues showed presence of P. gingivalis, and
25% T. forsythia, results that are similar to this study.
One of the options for diagnosing peri-implant disease
is peri-implant sulcus fluid (PISF) analysis, which offerseri-implantitis and patients with healthy implants (pg/ml).
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peri-implant disease, and may provide an early indica-
tion of those patients at risk of developing active disease
[16]. In the present study, PISF volume was greater in the
healthy implants (91.7 ± 50.3) than in the peri-implantitis
group (83.9 ± 43.1), though the difference was not
statistically significant.
Many studies have examined the presence of cytokines
in patients with periodontitis [48-50]. Due to the simi-
larity between periodontitis and peri-implantitis, many
inflammatory markers have been evaluated for monitor-
ing peri-implant health and can indicate the presence of
either disease [51-53]. Bacterial products from periodon-
tal pathogens stimulate the production of inflammatory
mediators secreted in PISF, which cause the destruction
of the peri-implant tissues [17]. Certain cytokines have
been proposed as potentially valid diagnostic or prog-
nostic markers of periodontal or peri-implant tissue
destruction [16]. An increase in interleukin levels is
observed in patients with peri-implant disease, though
there is controversy over the effect of interleukins in
crevicular fluid and peri-implantitis in relation to im-
plant failure or the development of periimplant disease
[54]. The IL-10 is an anti-inflammatory cytokine, pro-
duced by T-helper 2 cells (Th2), macrophages and B
cells, which inhibits synthesis of pro-inflammatory cyto-
kines such as IL-1, IL-2, IL-6, IL-8, TNF-a and IFN-g
(interferon gamma) [55]. On the other hand, IL10 acts
as a B cell stimulator, enhancing B cell proliferation and
differentiation [56]. These facts suggest that IL10 can
play important roles in the regulation of celular and
humoral immune responses [57]. As regards IL-10,
Liskmann et al. (18) reported a higher concentration of
IL-10 in patients with peri-implantitis. In contrast,
Duarte et al. [58] observed no differences between
healthy subjects and patients with disease. Some studies
have previously shown interleukin-1ß (IL-1ß) in PISF to
be elevated in cases of peri-implantitis [52,59,60]. TNF-
α, a cytokine with some functions similar to those of
IL-1β, has been detected at sites affected by periodontitis
[61] TNF-α and IL-1β act synergistically to initiate the
cascade of inflammatory mediators [62]. IL-6 has pro-
inflammatory effects and is responsible for the collagen
resorption of gingival tissues [63], while IL-10 is an in-
hibitor of inflammation [64]. IL-8 acts as a potent
chemoattractant for neutrophils in gingival tissues [65].
In this study, it was found that IL-1β (p < 0.01), IL-6
(p < 0.01), IL-10 (p < 0.05) and TNF-α (p < 0.01) were
significantly increased at the sites with peri-implantitis,
while IL-8 was not.
The main component of soft and hard tissue destruc-
tion associated with periodontal disease is believed to be
the result of activation of the host immunoinflammatory
response to bacterial challenge [66]. IL-1 and IL-6 haveboth been found to be significantly elevated at diseased
periodontal sites compared with healthy or inactive sites
[67]. IL-1 has also been positively correlated with in-
creased probe depth and attachment loss [68]. Other
clinical data indicate that IL-6 levels are higher in refrac-
tory periodontitis, and increased granulocyte chemotactic
factor (GCF) levels correlate to gram-negative fimbriae
[69]. Based upon the increased expression of IL-1 and
IL-6 in inflamed gingiva and high levels of GCF in peri-
odontitis patients, several studies have suggested that
an increased production of these cytokines may play an
important role in periodontal tissue destruction [48].
Conclusions
An analysis has been made of the clinical, microbiological
and host response aspects in implants with peri-implantitis.
The results of the present study involving a limited patient
sample suggest that the peri-implant microbiota and which
dental arch was rehabilitated involved could contribute to
bone loss in peri-implantitis. A significant relationship is
observed between the concentration of cytokines (interleu-
kins 1β, 6 and 10 and TNF-α) and the inflammatory
response in peri-implantitis tissue.
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